Neil Versel
Neil Versel is an editor at GenomeWeb. He covers the life science and healthcare informatics markets.
Articles Authored by Neil Versel
With Tempus Test Integration, CureMD Wants Genomics to Inform Oncology Clinical Decision Support
Premium
The specialty EHR vendor is building a two-way interface with Tempus as a model for incorporating genomic test ordering and results return into oncology workflows.
Working with EHR vendor Meditech to integrate genomics into clinical decision support, Frederick Health looks to prove the value of pharmacogenomics for all.
With $50M Investment in MOSAIC Project, Owkin Seeks to Become Cancer 'Drug Discovery Enterprise'
Premium
The MOSAIC research coalition brings together Owkin, NanoString, and European and US institutions to create a massive spatial omics dataset in pursuit of novel cancer biomarkers
With $13 million in new funding in hand, the small bioinformatics company aims to take on Big Pharma and will look to partner with major molecular labs.
Transcriptomic Classification of Pediatric Cancers Shows Potential to Improve Clinical Diagnoses
Premium
In a new paper, computational biologists at Toronto's Hospital for Sick Children described their atlas of childhood cancer subtypes and a corresponding search tool.
Genomic Testing Cooperative Implementing AI, Molecular Profiling to Improve Cancer Diagnosis
Premium
In a recent paper, GTC and its partners validated their RNAnalysis and TraceWork algorithms for targeted transcriptome and clinical decision support.
The companies have expanded their partnership to include GE's Fabric technology as they seek to predict response to metastatic non-small cell lung cancer therapies.
Tempus hopes to get the right patients into genetic sequencing, targeted therapies, and clinical trials with its Edge AI platform and NAPA digital pathology data network.
In AMIA Keynote, U of Chicago's Olopade Calls for More Diverse Data to Inform Precision Medicine
Premium
Genetic oncologist and informatician Olufunmilayo Olopade called for greater diversification of genomic datasets to inform early interventions in high-risk communities.
The bioinformatics firm hopes its AI and "NASA-style" command center will make it easier to get cancer patients into NGS labs and improve trial matching.